TW200819137A - Method for preparation of lipid-spacer radical- reactions of functional group-peptide - Google Patents

Method for preparation of lipid-spacer radical- reactions of functional group-peptide Download PDF

Info

Publication number
TW200819137A
TW200819137A TW095140210A TW95140210A TW200819137A TW 200819137 A TW200819137 A TW 200819137A TW 095140210 A TW095140210 A TW 095140210A TW 95140210 A TW95140210 A TW 95140210A TW 200819137 A TW200819137 A TW 200819137A
Authority
TW
Taiwan
Prior art keywords
group
peptide
lipid
amino acid
spacer
Prior art date
Application number
TW095140210A
Other languages
English (en)
Chinese (zh)
Other versions
TWI362270B (https=
Inventor
Te-We Lee
Shu-Pei Chiu
Chiu-Yu Yu
Tsui-Jung Chang
Chih-Hsien Chang
Original Assignee
Iner Aec Executive Yuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iner Aec Executive Yuan filed Critical Iner Aec Executive Yuan
Priority to TW095140210A priority Critical patent/TW200819137A/zh
Priority to US11/608,836 priority patent/US20080102110A1/en
Priority to JP2006350627A priority patent/JP2008115147A/ja
Priority to US12/029,324 priority patent/US20080139703A1/en
Publication of TW200819137A publication Critical patent/TW200819137A/zh
Application granted granted Critical
Publication of TWI362270B publication Critical patent/TWI362270B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW095140210A 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide TW200819137A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide
US11/608,836 US20080102110A1 (en) 2006-10-31 2006-12-10 Method for Preparing Lipid-Spacer-Reactive Functional Group-Peptide
JP2006350627A JP2008115147A (ja) 2006-10-31 2006-12-26 脂質−スペーサ−官能基−ペプチドを製造する方法
US12/029,324 US20080139703A1 (en) 2006-10-31 2008-02-11 Method for Preparing Lipid-Spacer-Reactive Functional Group-Peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide

Publications (2)

Publication Number Publication Date
TW200819137A true TW200819137A (en) 2008-05-01
TWI362270B TWI362270B (https=) 2012-04-21

Family

ID=39330477

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095140210A TW200819137A (en) 2006-10-31 2006-10-31 Method for preparation of lipid-spacer radical- reactions of functional group-peptide

Country Status (3)

Country Link
US (2) US20080102110A1 (https=)
JP (1) JP2008115147A (https=)
TW (1) TW200819137A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108934A1 (en) * 2009-03-25 2010-09-30 Novartis Ag Pharmaceutical composition containing a drug and sirna
TWI397428B (zh) * 2009-12-29 2013-06-01 財團法人工業技術研究院 標的第四介白素受體之傳輸系統
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3062075D1 (en) * 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
EP0445606B1 (en) * 1990-02-27 1997-01-22 The Agency of Industrial Science and Technology Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides
AU2316997A (en) * 1996-02-27 1997-09-16 David H Thompson Liposomal delivery system
AU2620000A (en) * 1999-01-21 2000-08-07 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same

Also Published As

Publication number Publication date
JP2008115147A (ja) 2008-05-22
US20080139703A1 (en) 2008-06-12
US20080102110A1 (en) 2008-05-01
TWI362270B (https=) 2012-04-21

Similar Documents

Publication Publication Date Title
CN103550781B (zh) 树状大分子自组装药物载体及其制备方法和应用
CN113024638B (zh) 一种小分子肽及其作为纳米载药载体的制备方法和应用
JP6368304B2 (ja) 生物活性化合物の送達に有用な機能性リポソーム
Ciccione et al. Unambiguous and controlled one-pot synthesis of multifunctional silica nanoparticles
Ringhieri et al. Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells
CN113292635B (zh) 靶向cd47的多肽及其应用
CN115154419B (zh) 一种纳米胶束前体和纳米胶束，其制备方法及应用
JP2008505049A (ja) ターゲティング組成物及びその製造方法
CN115700257A (zh) 一系列trop-2蛋白靶向多肽
CN110522923A (zh) 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料
TW200819137A (en) Method for preparation of lipid-spacer radical- reactions of functional group-peptide
CN119570739A (zh) 一种靶向Trop2的嵌合抗原受体巨噬细胞及其制备方法与应用
WO2006118327A1 (ja) カチオン性アミノ酸型脂質
CN111166892A (zh) 生物素和穿膜肽共同介导的乳腺癌靶向智能脂质体材料
CN109475638A (zh) 使用碳硅烷树状高分子的靶组织特异性递送型药物递送系统用胶囊
WO2024041372A1 (zh) 一种用于有效递送核酸的分支链结构多肽载体及其变化形式
US20220162259A1 (en) Peptide complex and production method therefor, and use of said peptide complex
US11352390B2 (en) Peptoid compound and preparation method, carrier, and pharmaceutical composition thereof
KR102521421B1 (ko) 헤테로키랄 펩티드 복합체 및 이의 자가조립 중간체를 포함한 핵자기공명분광 잔류쌍극결합 측정용 조성물
Singh et al. Access to diverse glutamic acid dendrons and a janus peptide dendrimer using an atypical solid phase synthesis
CN121265536B (zh) 一种rvg29修饰载齐考诺肽脂质体、制备方法和应用
Morisco et al. Peptide‐labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells
US11952433B2 (en) Heterochiral peptide-complex and composition for measuring nuclear magnetic resonance spectroscopy residual dipolar coupling containing self-assembled intermediates of heterochiral peptide-complex
CN120899934B (zh) 一种免疫调控手性材料及其制备方法与应用
CN111233975A (zh) 可靶向整合素的多肽mn及其在制备肿瘤靶向药物中的应用

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees